Header Logo

Connection

Michael Levy to Drug-Eluting Stents

This is a "connection" page, showing publications Michael Levy has written about Drug-Eluting Stents.
Connection Strength

2.184
  1. Ganatra S, Sharma A, Levy MS. Re-Evaluating the Safety of Drug-Eluting?Stents in Cancer Patients. JACC Cardiovasc Interv. 2017 11 27; 10(22):2334-2337.
    View in: PubMed
    Score: 0.561
  2. Bang VV, Levy MS. Duration of dual anti-platelet therapy following drug eluting stents: Less Is More? Catheter Cardiovasc Interv. 2016 Mar; 87(4):733-4.
    View in: PubMed
    Score: 0.497
  3. Majithia A, Levy MS. Drug eluting stents in primary PCI: ready for prime-time? Catheter Cardiovasc Interv. 2014 Nov 15; 84(6):963-4.
    View in: PubMed
    Score: 0.455
  4. Parikh PP, Levy MS. Drug-eluting stents and diabetes: a generation gap? Catheter Cardiovasc Interv. 2013 Jun 01; 81(7):1115-6.
    View in: PubMed
    Score: 0.411
  5. Ganatra S, Sharma A, Levy MS. A Differing Opinion on Primary Percutaneous Coronary Intervention in Patients Who Have Had Cancer: Stent Choice in Onco-cardiology Revisited. Mayo Clin Proc. 2017 08; 92(8):1315-1316.
    View in: PubMed
    Score: 0.137
  6. Sharma AK, Levy MS. Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population--the future is now? Catheter Cardiovasc Interv. 2015 Nov 15; 86(6):982-3.
    View in: PubMed
    Score: 0.122
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.